Matches in SemOpenAlex for { <https://semopenalex.org/work/W1979895891> ?p ?o ?g. }
Showing items 1 to 92 of
92
with 100 items per page.
- W1979895891 endingPage "S40" @default.
- W1979895891 startingPage "S40" @default.
- W1979895891 abstract "Background: Long-term anticoagulation therapy with warfarin is recommended for LVAD patients. Compared to other warfarin-treated patients, the LVAD population has a higher rate of suboptimal INRs and a lower average time in the therapeutic window. Suboptimal anticoagulation is a major reason for hospital readmission. We describe our experience with the use of half-dose enoxaparin (0.5 mg/kg/dose) bridging therapy, as a potential alternative to hospital readmission for LVAD-patients with subtherapeutic INRs who may be at higher risk of thrombotic events. Methods: LVAD outpatients with sub-therapeutic INRs were selected to receive half therapeutic dose enoxaparin as bridge therapy based on our VAD anticoagulation protocol. Selection criteria included current INR, VAD type and timing of implantation, history of bleeding or thrombotic events, renal function, medication adherence, and ability to effectively administer enoxaparin injections. The general threshold for bridging was an INR ! 1.6. Enoxaparin was dosed as 0.5 mg/kg every 12 hours. Outpatient INR monitoring and follow-up was conducted by the VAD Coordinator and pharmacist. Within 24 hours of initiation of therapy, a pharmacist telephoned the patient to reinforce proper administration technique and to answer medication-specific questions. Additional telephone communications were conducted by the pharmacist and VAD Coordinator to assess for bleeding complications and duration of therapy. Patients are monitored routinely for thrombus at each ambulatory clinic visit. Results: During the initial 6 months of this program, 15 patients (11 HeartMate II, 3 HeartWare LVAD, 1 Heartware BiVad) were treated with half-dose enoxaparin. The mean INR upon initiation of therapy was 1.4 (range 1.2 to 1.7). Patients received an average of 7.2 enoxaparin doses (range 4 to 14) for a mean duration of therapy of 3.5 days (range 2 to 7). In total, 108 doses were administered accounting for 54 patient days of therapy. No patient was admitted to a hospital due to bleeding or thrombotic events. Minor bleeding, described as mild bleeding at the injection site and increased bruising, was reported in 5 patients (30%). During the observation period, 14 patients (93.3%) completed the protocol with achievement of a therapeutic INR; one patient discontinued therapy due to hospital admission not related to anticoagulation management. Conclusion: In this small series, half-dose enoxaparin appears to be a feasible strategy to bridge selected ambulatory VAD patients with sub-therapeutic INRs. Further investigation is needed to determine its safety and efficacy in a larger population of patients" @default.
- W1979895891 created "2016-06-24" @default.
- W1979895891 creator A5000150514 @default.
- W1979895891 creator A5003235003 @default.
- W1979895891 creator A5013872275 @default.
- W1979895891 creator A5019258068 @default.
- W1979895891 creator A5023201868 @default.
- W1979895891 creator A5024163715 @default.
- W1979895891 creator A5038633666 @default.
- W1979895891 creator A5068161236 @default.
- W1979895891 creator A5084244205 @default.
- W1979895891 date "2013-08-01" @default.
- W1979895891 modified "2023-09-26" @default.
- W1979895891 title "Cognitive Behavioral Therapy by iPad for Caregivers: A Pilot Study" @default.
- W1979895891 doi "https://doi.org/10.1016/j.cardfail.2013.06.134" @default.
- W1979895891 hasPublicationYear "2013" @default.
- W1979895891 type Work @default.
- W1979895891 sameAs 1979895891 @default.
- W1979895891 citedByCount "0" @default.
- W1979895891 crossrefType "journal-article" @default.
- W1979895891 hasAuthorship W1979895891A5000150514 @default.
- W1979895891 hasAuthorship W1979895891A5003235003 @default.
- W1979895891 hasAuthorship W1979895891A5013872275 @default.
- W1979895891 hasAuthorship W1979895891A5019258068 @default.
- W1979895891 hasAuthorship W1979895891A5023201868 @default.
- W1979895891 hasAuthorship W1979895891A5024163715 @default.
- W1979895891 hasAuthorship W1979895891A5038633666 @default.
- W1979895891 hasAuthorship W1979895891A5068161236 @default.
- W1979895891 hasAuthorship W1979895891A5084244205 @default.
- W1979895891 hasConcept C104863432 @default.
- W1979895891 hasConcept C126322002 @default.
- W1979895891 hasConcept C141071460 @default.
- W1979895891 hasConcept C194828623 @default.
- W1979895891 hasConcept C2776301958 @default.
- W1979895891 hasConcept C2778198053 @default.
- W1979895891 hasConcept C2778774980 @default.
- W1979895891 hasConcept C2779161974 @default.
- W1979895891 hasConcept C2779326848 @default.
- W1979895891 hasConcept C2779457091 @default.
- W1979895891 hasConcept C2781362458 @default.
- W1979895891 hasConcept C2908647359 @default.
- W1979895891 hasConcept C35785553 @default.
- W1979895891 hasConcept C512399662 @default.
- W1979895891 hasConcept C71924100 @default.
- W1979895891 hasConcept C99454951 @default.
- W1979895891 hasConceptScore W1979895891C104863432 @default.
- W1979895891 hasConceptScore W1979895891C126322002 @default.
- W1979895891 hasConceptScore W1979895891C141071460 @default.
- W1979895891 hasConceptScore W1979895891C194828623 @default.
- W1979895891 hasConceptScore W1979895891C2776301958 @default.
- W1979895891 hasConceptScore W1979895891C2778198053 @default.
- W1979895891 hasConceptScore W1979895891C2778774980 @default.
- W1979895891 hasConceptScore W1979895891C2779161974 @default.
- W1979895891 hasConceptScore W1979895891C2779326848 @default.
- W1979895891 hasConceptScore W1979895891C2779457091 @default.
- W1979895891 hasConceptScore W1979895891C2781362458 @default.
- W1979895891 hasConceptScore W1979895891C2908647359 @default.
- W1979895891 hasConceptScore W1979895891C35785553 @default.
- W1979895891 hasConceptScore W1979895891C512399662 @default.
- W1979895891 hasConceptScore W1979895891C71924100 @default.
- W1979895891 hasConceptScore W1979895891C99454951 @default.
- W1979895891 hasIssue "8" @default.
- W1979895891 hasLocation W19798958911 @default.
- W1979895891 hasOpenAccess W1979895891 @default.
- W1979895891 hasPrimaryLocation W19798958911 @default.
- W1979895891 hasRelatedWork W1993593418 @default.
- W1979895891 hasRelatedWork W2000809210 @default.
- W1979895891 hasRelatedWork W2007586530 @default.
- W1979895891 hasRelatedWork W2022852716 @default.
- W1979895891 hasRelatedWork W2042477514 @default.
- W1979895891 hasRelatedWork W2065129517 @default.
- W1979895891 hasRelatedWork W2092212595 @default.
- W1979895891 hasRelatedWork W2589110857 @default.
- W1979895891 hasRelatedWork W2595202867 @default.
- W1979895891 hasRelatedWork W2719879046 @default.
- W1979895891 hasRelatedWork W2739865103 @default.
- W1979895891 hasRelatedWork W2804476147 @default.
- W1979895891 hasRelatedWork W2808856572 @default.
- W1979895891 hasRelatedWork W2919856695 @default.
- W1979895891 hasRelatedWork W3015050193 @default.
- W1979895891 hasRelatedWork W3029964941 @default.
- W1979895891 hasRelatedWork W3084132833 @default.
- W1979895891 hasRelatedWork W3095617971 @default.
- W1979895891 hasRelatedWork W3137018961 @default.
- W1979895891 hasRelatedWork W35849137 @default.
- W1979895891 hasVolume "19" @default.
- W1979895891 isParatext "false" @default.
- W1979895891 isRetracted "false" @default.
- W1979895891 magId "1979895891" @default.
- W1979895891 workType "article" @default.